0000874716-26-000038
SEC filingIDEXX Laboratories, Inc. reported strong financial performance for fiscal year 2025, with total revenue of $4.30 billion and net income of $1.06 billion. The company generated a gross profit of $2.66 billion from total cost of revenue of $1.64 billion, resulting in income from operations of $1.36 billion. Operating expenses totaled $1.30 billion, comprising sales and marketing ($643.5 million), general and administrative ($404.8 million), and research and development ($251.2 million). The company maintained solid cash flow from operations of $1.18 billion, though net cash decreased by $108.2 million due to significant stock repurchases of $1.22 billion and investing activities of $136.2 million. The balance sheet shows total assets of $3.35 billion, with current assets of $1.41 billion and stockholders' equity of $1.61 billion. Earnings per share were $13.00 for both basic and diluted calculations.
IDEXX Laboratories, Inc. delivered robust financial results for fiscal year 2025, achieving total revenue of $4.30 billion and net income of $1.06 billion. The company maintained strong profitability with gross profit of $2.66 billion and income from operations of $1.36 billion. Operating expenses were well-controlled at $1.30 billion, representing 30.2% of total revenue. The company generated substantial cash flow from operations of $1.18 billion, though net cash decreased by $108.2 million due to significant financing activities including $1.22 billion in stock repurchases. Earnings per share were $13.00 for both basic and diluted calculations, based on weighted average shares outstanding of 80.4 million basic and 81.0 million diluted.
The filing does not provide segment breakdown or geographic mix data for revenue analysis. The XBRL data shows total revenue of $4.30 billion but does not disclose product versus service revenue breakdown or any segment-level information. No growth drivers or revenue composition details are provided in the available data. The document content and XBRL financial data sections contain identical information, with no additional revenue analysis or segment disclosures beyond the aggregate total revenue figure.
IDEXX demonstrated strong margin performance with a gross margin of 61.9% based on gross profit of $2.66 billion from total revenue of $4.30 billion. The operating margin was 31.6% with operating income of $1.36 billion. The cost structure shows total cost of revenue at $1.64 billion, representing 38.1% of revenue. Operating expenses totaled $1.30 billion, comprising sales and marketing ($643.5 million, 15.0% of revenue), general and administrative ($404.8 million, 9.4% of revenue), and research and development ($251.2 million, 5.8% of revenue). The company maintained healthy profitability with net income margin of 24.7%.
The company generated strong operating cash flow of $1.18 billion, with free cash flow of $1.04 billion (operating cash flow of $1.18 billion minus capital expenditures of $124.7 million and acquisitions of intangible assets of $13.6 million). The balance sheet shows total assets of $3.35 billion, including current assets of $1.41 billion (cash and equivalents $180.1 million, accounts receivable $552.4 million, inventories $377.8 million). Total liabilities were $1.75 billion, with current liabilities of $1.15 billion and long-term debt of $374.8 million. Stockholders' equity stood at $1.61 billion, resulting in a debt-to-equity ratio of 23.3%. The company maintained solid liquidity with current ratio of 1.23.
The filing does not contain management guidance, strategic priorities, or specific risk factors in the provided document content. The XBRL financial data and document text sections are identical and focus exclusively on historical financial statements without forward-looking statements or outlook information. No qualitative discussion of business strategy, market conditions, or future expectations is included in the available data. The analysis is limited to the reported financial results for fiscal year 2025 without projection or guidance for future periods.